Scholar Rock Resubmits Apitegromab BLA After FDA Site Inspection Issues
Event summary
- Scholar Rock resubmitted the Biologics License Application (BLA) for apitegromab, a muscle-targeted therapy for spinal muscular atrophy (SMA), to the FDA on March 31, 2026.
- The resubmission follows a Complete Response Letter (CRL) in September 2025 related to observations at Catalent Indiana's site, which were not specific to apitegromab.
- Scholar Rock added a second U.S.-based fill-finish facility to strengthen the supply chain and support future demand.
- The FDA has granted Fast Track, Orphan Drug, Priority Review, and Rare Pediatric Disease designations to apitegromab.
The big picture
Scholar Rock's resubmission of the BLA for apitegromab marks a critical step in addressing regulatory hurdles related to manufacturing site inspections. The addition of a second fill-finish facility underscores the company's focus on scaling production to meet anticipated demand, reflecting broader industry trends toward robust supply chain management in biopharmaceuticals. The strategic context includes the competitive landscape for SMA treatments and the potential for apitegromab to differentiate itself as a muscle-targeted therapy.
What we're watching
- Regulatory Timing
- Whether the FDA will accept the BLA within the anticipated 30-day window and complete its review by the PDUFA action date in late September 2026.
- Supply Chain Execution
- The pace at which Scholar Rock can operationalize the second fill-finish facility to meet growing demand for apitegromab.
- Market Expansion
- How the European Medicines Agency (EMA) review progresses and whether a mid-2026 decision will align with U.S. approval timelines.